Brief: Equillium Announces Plans To Initiate Phase 3 Pivotal Study Of Itolizumab In First-Line Treatment Of Acute Graft-Versus-Host Disease Following End-Of-Phase 1 Meeting With The FDA

Equillium

12/07/2021 21:06

July 12 (Reuters) - Equillium Inc  EQ.O :
    * EQUILLIUM ANNOUNCES PLANS TO INITIATE PHASE 3 PIVOTAL
STUDY OF
ITOLIZUMAB IN FIRST-LINE TREATMENT OF ACUTE GRAFT-VERSUS-HOST
DISEASE FOLLOWING END-OF-PHASE 1 MEETING WITH THE FDA
    * EQUILLIUM INC - ON TRACK TO INITIATE STUDY IN Q4 2021
    * EQUILLIUM INC - FINALIZING DETAILS OF PHASE 3 PROTOCOL
BASED ON
FEEDBACK AND GUIDANCE FROM FDA

Source text for Eikon:  ID:nGNX5l7Hr6 
Further company coverage:  EQ.O 

 ((Reuters.Briefs@thomsonreuters.com;))